While this medical condition cannot be reversed, medications and injections have been found to be effective in the reducing the pain caused due to osteoarthritis.Drugs such as NSAIDs, analgesics, corticosteroids, and viscosupplement agents are being used widely to manage osteoarthritis.Global Leaders:The osteoarthritis therapeutics market is a highly fragmented market and has presence of various players.The major players operating in this market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm.Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).Download PDF
[email protected]://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994Expected Revenue Growth:The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.Major Growth BoostersThe growth of this market is driven by significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries.Sanofi (France)Sanofi held the leading position in the global viscosupplementation agents market in 2019.In 2019, it invested USD 6.74 billion in R, which consisted of 16.7% of the company revenue.The company offers viscosupplement-based injections for the treatment of osteoarthritis.